Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
for Resectable Intrahepatic Cholangiocarcinoma
Drug: Durvalumab
58 locations incl. Irvine
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06050252·Phase 2·Recruiting